TEVA Stock Recent News

Data is abundant, if not overwhelming, on Wall Street. Between earnings season -- the six-week period when a majority of S&P 500 companies unveil their quarterly operating results -- and near-daily economic data releases, it can be easy to miss something important.

Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a well-known name on Wall Street while working for George Soros until 2000.

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Leerink's 2025 Global Healthcare Conference March 12, 2025 8:40 AM ET Company Participants Richard Francis - CEO Unidentified Company Representative Hi. Good morning, everybody.

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:00 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. My name is Balaji Prasad.

Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and Uzedy face challenges, with Austedo's future revenue potentially affected by IRA negotiations and tepid growth projections for Ajovy and Uzedy. Teva's experimental IBD drug, duvakitug, shows promise with positive mid-stage data, but its future hinges on successful Phase 3 trials and market competition.

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in March as follows:

The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL) announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA).

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference February 24, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Eric Hughes - Head of R&D & Chief Medical Officer Vipul Jairath - Professor at Western University Conference Call Participants Umer Raffat - Evercore ISI Ash Verma - UBS David Amsellem - Piper Sandler Jason Gerberry - Bank of America Chris Schulz - J.P. Morgan Operator Good morning or good afternoon all, and welcome to the Duvakitug Anti-TL1A Phase 2b Data Presentation from ECCO.

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025 PARSIPPANY, N.J. and PARIS, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.